Sève Pascal, Reiman Tony, Isaac Sylvie, Trillet-Lenoir Véronique, Lafanéchère Laurence, Sawyer Michael, Dumontet Charles
Université Claude Bernard Lyon 1, INSERM U 590, Lyon, France.
Anticancer Res. 2008 Mar-Apr;28(2B):1161-7.
To determine the prognostic value of microtubule component expression in tumors of patients with carcinomas of unknown primary site (CUP).
Class III beta-tubulin, Delta2-alpha-tubulin and tau protein were examined immunohistochemically in 51 CUP tumors from patients receiving paclitaxel and compared with their response to treatment.
The overall response rate was 18.4% among 49 evaluable patients. Delta2-alpha-Tubulin and tau were not correlated with response or patient outcome. High class III beta-tubulin expression was correlated with both resistance to chemotherapy and shorter overall survival, while there was no relation with progression-free survival. In multivariate analysis taking into account clinical factors, class III beta-tubulin expression was independently correlated with overall survival.
These findings show that in tumor cells a high level of expression of class III beta-tubulin, but not Delta2-alpha-tubulin or tau, is associated with resistance to paclitaxel and a poor prognosis in CUP patients receiving paclitaxel.
确定微管成分表达在原发部位不明的癌（CUP）患者肿瘤中的预后价值。
对51例接受紫杉醇治疗的CUP患者的肿瘤进行免疫组织化学检测，观察III类β-微管蛋白、Delta2-α-微管蛋白和tau蛋白，并与其治疗反应进行比较。
49例可评估患者的总缓解率为18.4%。Delta2-α-微管蛋白和tau与治疗反应或患者预后无关。III类β-微管蛋白高表达与化疗耐药和总生存期缩短相关，而与无进展生存期无关。在考虑临床因素的多变量分析中，III类β-微管蛋白表达与总生存期独立相关。
这些发现表明，在肿瘤细胞中，高水平表达的III类β-微管蛋白而非Delta2-α-微管蛋白或tau与接受紫杉醇治疗的CUP患者对紫杉醇的耐药性及不良预后相关。
